AGA Family of Websites:
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board

Insights on IBD: How Can We Achieve Long-Term Success?

Join host Neilanjan Nandi, MD, and leading IBD experts to learn successful treat-to-target strategies for your patients.

Achieving remission and long-term success in inflammatory bowel disease (IBD) is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation and do not possess broad immunosuppressive properties. Get started in selecting the right therapeutic strategy for your patients by completing Insights on IBD: How Can We Achieve Long-Term Success?, a free, four-part — 15-minute each — educational series hosted by Neilanjan Nandi, MD. 

  • First session: Goals of Managing IBD — Treating to Target

    Miguel Regueiro, MD, AGAF, and Dr. Nandi explore practical approaches to defining therapeutic success and provide listeners with solutions and recommendations to ultimately improve long-term IBD patient outcomes.

  • Second session: Achieving Long-Term Success in the Management of IBD

    Gary Lichtenstein, MD, AGAF, and Dr. Nandi break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient. 

  • Third session: New Viewpoints in the Management of IBD

    Russel Cohen, MD, AGAF, and Dr. Nandi explore the role of these targets in addressing the various unique IBD phenotypes that lead to loss of response over time, as well as provide practical insights into selecting the right therapy at the right time for your patient. 

  • Fourth session: Case Challenges in the Management of IBD

    Follow Sunanda Kane, MD, MSPH, AGAF, and Dr. Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenario of a patient with IBD. Would you make the same decisions? 

After participating in the four-part, educational activity, participants should be able to:

  • Apply guideline recommendations to optimize and individualize treatment for patients with IBD.
  • Assess current pharmacotherapy for IBD in terms of safety, efficacy and tolerability profiles.
  • Describe the role of treat-to-target strategies in improving long-term outcomes in patients with IBD.
  • Formulate treatment adjustments in patients who have become nonresponsive, experience diminished response or become refractory to initial treatment for IBD.
  • Assess emerging safety and efficacy data from clinical trials on biologic agents and small molecules that may potentially be used to treat IBD.

This series is provided by AGA and Prova Education, and supported by independent educational grants from AbbVie Inc., Bristol Myers Squibb and Takeda Pharmaceuticals.

Your hub for GI education is
AGA University

By using this site, you agree to our updated Privacy Policy.